Just a followup since the "much more quickly" quote was in regard to future trial length and I did not directly address that. I believe the SAP will be used to change future endpoints such that validation of positive effect will be correlated to biomarkers and treatment cell potency rather than just PFS or OS. With Direct, for instance, those that respond to treatment can be determined by DC cellular characteristics. That indicates to me that the potential to encorporate this into the L SAP is real and I would expect NWBO to take full advantage if this opportunity. Best wishes.
News 
Market Data 
Discover 
